drugset / Trial / NCT03384277

Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab

NCT03384277

RandomizedParallel-groupOpen-labelTreatment

Summary

Purpose: To evaluate the efficacy when administering steroid combined with single dose rituximab to eliminate the antibody in acquired hemophilia A patients compared to treatment using steroid with cyclophosphamide. The study will test the hypothesis that steroid combined with small dose rituximab is as effective as steroid combined with cyclophosphamide for FVIII inhibitor eradication in Chinese patients with acquired hemophilia A. Study design Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment

Timeline

Start
2017-12-29
Primary completion
2022-06-09
Completion
2022-07-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclophosphamide Other / unclassified 2 mg/kg
Subject Rituximab Monoclonal antibody 375 mg/m2
Background Methylprednisolone Other / unclassified 0.8 mg/kg

Indications